Finerenone Achieves Primary Endpoint in FIND-CKD Phase III Study for Non-Diabetic CKD
Finerenone has met its primary endpoint in the pivotal Phase III FIND-CKD study, demonstrating significant efficacy for patients with non-diabetic chronic kidney disease. These results underscore finerenone’s potential to expand therapeutic options in CKD beyond the diabetic population.